Angiotensin-(1-7): Non-Toxic, Targeted Cancer Therapeutic

Market Need

Toxic chemotherapies, the standard for treating most cancers, contribute to poor quality of life for patients. Treating patients with Wake Forest University’s therapeutic Angiotensin-(1-7) [Ang-(1-7)] is a safe and effective alternative that inhibits cancer cell growth with little or no toxicities and side effects. Ang-(1-7) has shown anti-cancer effects in breast, prostate, and lung cancers and sarcomas, demonstrating its potential for use in a wide range of clinical settings.

Competitive Benefits

  • Ang-(1-7) specifically targets solely proliferating cells, i.e. cancer cells, thus minimizing side effects attributed to undesired targeting of healthy cells.
  • Ang-(1-7) shows anti-cancer effects in many cancer types, including cancers of the lung, breast, prostate and sarcomas.
  • Ang-(1-7) does not produce alterations in blood pressure, heart rate or wound healing when used for the treatment of cancer.
  • Ang-(1-7) and its analogs appear to act at the MAS oncogenic receptor, in a novel mechanism to have shown translational validation.

Application Fields

  • Treatment of sarcomas and lung, breast, prostate and connective tissue cancers
  • May also be used to treat non-solid tumors


  • A successful phase II clinical trial of Ang-(1-7) for second or third line treatment of patients with metastatic or unresectable sarcomas is complete.
  • Phase I Clinical Trials have been completed for the study of Ang-(1-7) in the treatment of solid tumors in human patients.
  • Ang-(1-7) has demonstrated effective inhibition of cancer cell growth in vitro and tumor growth in mouse models.
  • Assessment of the molecular mechanisms targeted by Ang-(1-7) to mediate its anti-cancer effects are currently ongoing.
  • Inventors are pursuing an active development program for next generation Ang-(1-7) products and formulations, including new lead compounds with profiles superior to Ang-(1-7) in preclinical animal models.
  • Access to these new analogs and the data will be provided under appropriate confidentiality obligations.


  • E. Ann Tallant, PhD
  • Patricia E. Gallagher, PhD
  • Carlos M. Ferrario, MD


US Patent No. 8,034,781
US Patent No. 7,122,523
US Patent No. 7,375,073


Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone. Clin Cancer Res. 2009 Dec 1;15 (23):7398-404.

Licensing Contact

Michael Batalia

Back to Top